Seroquel
In brief
- In Australia Seroquel (quetiapine) is normally supplied from pharmacies and hospitals and is prescription-only; some sellers or pharmacies may offer it without a receipt, but obtaining or using prescription medicines without a valid prescription is unsafe and not recommended.
- Seroquel is used for schizophrenia, acute and maintenance bipolar disorder (mania and bipolar depression) and as an adjunct for major depressive disorder; it is an atypical (second‑generation) antipsychotic that primarily antagonises serotonin 5‑HT2A and dopamine D2 receptors, and also has activity at histamine H1 and alpha‑1 adrenergic receptors (contributing to sedation and orthostatic effects).
- Usual doses vary by indication: schizophrenia adults often titrated to 300–400 mg/day (in 2–3 divided doses) with a max of 800 mg; acute bipolar mania typically starts low and can reach 400 mg by Day 4 (max 800 mg); bipolar depression and adjunctive use commonly use 50 mg nightly titrated to 300 mg (max 300 mg for depression); lower starting doses and slower titration are used in children, the elderly and with liver impairment.
- Administered orally as immediate‑release tablets (25–400 mg strengths) typically given once or twice daily, or as extended‑release (XR) tablets (50–400 mg) usually once daily at bedtime; do not crush or chew XR tablets.
- Sedation or drowsiness can occur rapidly, often within 30–60 minutes; therapeutic antipsychotic or mood effects typically take several days to weeks to become evident (often 1–6 weeks depending on the symptom and dose).
- Duration of action depends on formulation: immediate‑release effects are generally covered by twice‑daily dosing (half‑life ~6 hours), while XR formulations are designed to provide more sustained levels with once‑daily dosing and a longer effective duration; clinical effects may require ongoing daily dosing for maintenance.
- Do not drink alcohol while taking Seroquel — alcohol increases sedation, respiratory depression and risk of orthostatic hypotension and other adverse effects.
- The most common side effect is drowsiness/sedation; other frequent effects include dizziness, dry mouth, constipation, weight gain, increased appetite, orthostatic hypotension and mild tachycardia.
- Would you like to try “seroquel” without a prescription?
Basic Seroquel Information
- INN (International Nonproprietary Name): Quetiapine
- Brand Names Available In Australia: not specified
- ATC Code: N05AH04
- Forms & Dosages: Immediate‑release tablets 25mg–400mg; Extended‑release (XR) tablets 50mg–400mg
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: Prescription (Rx) only
Latest Research Findings
Clinicians ask whether new studies change how quetiapine is used in practice.
European and Austrian research from 2022–2025 focused on real‑world outcomes, metabolic safety and dose optimisation for quetiapine.
Registry and pharmacoepidemiology analyses across EU and Austrian datasets show continued efficacy in acute mania and bipolar depression.
Pharmacovigilance reports identified weight gain and dyslipidaemia as the most frequent long‑term harms in inpatient cohorts.
Randomised controlled trials in the period reaffirm regulatory indications for schizophrenia, bipolar mania and adjunctive major depressive disorder.
Safety reviews emphasise increased risk and caution in elderly patients with dementia‑related psychosis.
Extended‑release formulations reduced early morning sedation compared with immediate‑release in some observational cohorts.
Evidence level is a mix of RCTs and registry analyses, with limitations in observational Austrian data such as confounding and local prescribing patterns.
| Trial Type | Population | Timeframe | Primary Outcome | Safety Signal |
|---|---|---|---|---|
| Randomised Controlled Trial (RCT) | Adults with schizophrenia or bipolar disorder | 2022–2025 | Symptom reduction (PANSS/MADRS/CGI) | Standard adverse effects; dementia warning reiterated |
| Registry/Observational | Real‑world users across EU registries | 2022–2025 | Hospitalisation, treatment persistence | Metabolic markers, weight gain, dyslipidaemia |
| Austrian Pharmacoepidemiology Audits | Inpatient psychiatric populations | 2022–2025 | Prescribing frequency, formulary placement | Weight gain and dyslipidaemia most frequent long‑term harms |
Data highlights: monitoring of fasting glucose, HbA1c and lipids was emphasised in Austrian cohorts.
Discontinuation rates in observational studies were often driven by sedation or metabolic concerns, and tended to be higher in immediate‑release cohorts compared with XR in some datasets.
Real data: ATC N05AH04; forms/doses—IR 25–400mg; XR 50–400mg; branded listings—Seroquel, Seroquel XR.
Clinical Effectiveness In Austria
Patients and prescribers want to know how well quetiapine performs in local care settings.
In Austrian clinical practice quetiapine is used across inpatient psychiatric wards and community mental health services.
Socialversicherung prescription‑claim analyses and e‑medication records indicate frequent use for bipolar disorder and schizophrenia.
Adjunctive use in treatment‑resistant depression is rising in specialist clinics.
Reported outcomes include symptomatic improvement in acute mania and mood stabilisation during maintenance treatment.
Faster onset of sedation is valued for agitated patients but can complicate daytime functioning and return‑to‑work planning.
Hospitals often favour XR formulations where adherence is problematic or morning sedation is disruptive.
Pharmacists report switching between Seroquel and generics depending on reimbursement and supply considerations.
Outcome Measures:
- PANSS: Positive And Negative Syndrome Scale (schizophrenia symptom load)
- MADRS: Montgomery‑Åsberg Depression Rating Scale (depressive symptoms)
- CGI: Clinical Global Impression (overall clinical status)
| Indication | Typical Target Dose |
|---|---|
| Schizophrenia | 300–400mg/day (divided) |
| Bipolar Depression | 300mg at bedtime |
| Acute Mania | Up to 400mg by Day 4 (escalate per tolerability) |
| Adjunct MDD (XR) | 50–300mg XR at bedtime |
Real‑world Austrian cohorts stress the need for routine monitoring of weight, lipids and glucose, and for coordination between psychiatrists and primary care via the e‑medication system.
Indications And Extended Uses
People often ask what quetiapine is approved for and what uses are off‑label.
Regulatory indications reflected in European practice include schizophrenia, bipolar mania and bipolar depression.
Quetiapine XR is authorised as an adjunct in major depressive disorder in select populations.
Standard dosage guidance from real data:
- Schizophrenia target 300–400mg/day (max 800mg).
- Bipolar depression titrate to 300mg at bedtime (max 300mg).
- Acute mania escalate to 400mg by Day 4 (max 800mg).
Off‑label use in Austria and neighbouring settings includes low‑dose quetiapine for insomnia and short‑term use for agitation in dementia despite warnings.
Off‑label prescribing is common in primary care and emergency settings but attracts caution from pharmacists and clinicians because of limited evidence and safety concerns.
| Indication | Regulatory Status (EMA/Austria) | Typical Target Dose |
|---|---|---|
| Schizophrenia | Approved | 300–400mg/day |
| Bipolar Mania | Approved | Up to 400mg by Day 4 |
| Bipolar Depression | Approved | 300mg at bedtime |
| Adjunct In Major Depressive Disorder (XR) | Approved as adjunct | 50–150–300mg XR at bedtime |
| Insomnia (low dose) | Off‑label | Low nightly doses (clinical judgement) |
Off‑label Defined:
- Off‑label = clinical judgement + informed consent + documented rationale.
Composition And Brand Overview
Patients want to know what is in the tablet and who manufactures it.
The active ingredient is quetiapine, commonly supplied as quetiapine fumarate in commercial formulations.
Brand landscape mirrors international markets with AstraZeneca’s Seroquel and Seroquel XR plus multiple generics.
Packaging is typically blister packs of 10, 30, 60 or 100 tablets; some markets use child‑resistant packs.
No parenteral, liquid or topical forms—oral tablets only.
| Brand | Formulation | Typical Pack Sizes |
|---|---|---|
| Seroquel | Immediate‑release tablets 25–400mg | 10, 30, 60, 100 tablets |
| Seroquel XR | Extended‑release tablets 50–400mg | 10, 30, 60 tablets |
| Generic Quetiapine | IR and XR formulations | 10, 30, 60, 100 tablets |
- Major manufacturers/suppliers referenced in product listings: AstraZeneca, Teva, Sandoz, Mylan, Sun Pharma, Aurobindo, Dr. Reddy’s, Accord Healthcare.
- Label variations may include Quetiapina, Quétiapine or Quetiapinum for cross‑border patients.
Procurement realities: hospitals often tender generics and community pharmacies stock a mix depending on Sozialversicherung reimbursement and supply.
Contraindications And Special Precautions
People commonly want to know when quetiapine should not be used.
Absolute contraindication: known hypersensitivity to quetiapine or excipients.
Quetiapine is not indicated for dementia‑related psychosis due to increased mortality risk in the elderly.
Relative contraindications requiring close monitoring include cardiovascular disease, arrhythmias, cerebrovascular history, liver impairment, diabetes risk, seizure disorders and history of leukopenia or cataracts.
Advise patients not to drive or operate heavy machinery during initiation or dose escalation because of sedation and orthostatic hypotension.
Assess fall risk in elderly patients and consider slower titration.
Recommend a baseline ECG where clinically indicated, especially with QT‑prolonging co‑medications.
- Absolute Contraindication: Hypersensitivity to quetiapine or excipients.
- Relative Contraindications: Cardiovascular disease, liver impairment, seizure disorder, diabetes risk, history of neutropaenia.
Practical pharmacy counselling checklist: review medication history for QT risk, counsel on orthostatic symptoms and document monitoring arrangements with prescriber.
Dosage Guidelines
Patients frequently ask how to start and what dose to aim for.
Schizophrenia (adults): start 25mg twice daily, titrate to 300–400mg/day in divided doses; max 800mg.
Bipolar mania (acute): start 50mg twice daily and escalate to 400mg by Day 4; max 800mg depending on tolerability.
Bipolar depression: start 50mg nightly and titrate to 300mg at bedtime; max 300mg.
Adjunctive MDD: XR 50mg at bedtime, may increase to 150–300mg XR at bedtime as needed.
Children/adolescents: use lower starting doses; approved for schizophrenia ≥13 years and bipolar mania ≥10 years with conservative titration.
Elderly and liver impairment: start low (for example 25mg/day) and titrate slowly due to hepatic metabolism and sensitivity.
| Indication | Starting Dose | Target Dose | Max Dose |
|---|---|---|---|
| Schizophrenia (Adults) | 25mg twice daily | 300–400mg/day | 800mg |
| Bipolar Mania (Acute) | 50mg twice daily | 400mg by Day 4 | 800mg |
| Bipolar Depression | 50mg nightly | 300mg at bedtime | 300mg |
| Adjunct MDD (XR) | 50mg XR at bedtime | 150–300mg XR at bedtime | 300mg |
- Take XR at bedtime and do not crush or chew the XR tablets.
- If a dose is missed, take as soon as remembered unless it is near the next dose; do not double dose.
Overview Of Drug Interactions
Patients ask which medicines or substances change how quetiapine works.
Quetiapine is mainly metabolised by hepatic CYP pathways, especially CYP3A4.
Strong CYP3A4 inhibitors such as ketoconazole increase quetiapine plasma levels and may require dose reduction or avoidance.
CYP3A4 inducers such as carbamazepine reduce quetiapine exposure and may lower effectiveness.
Alcohol potentiates sedation and orthostatic effects and should be avoided during initiation and dose changes.
Caffeine may mask sedation and increase restlessness or anxiety in some patients.
| Interacting Agent | Effect On Quetiapine | Practical Action |
|---|---|---|
| Ketoconazole (strong CYP3A4 inhibitor) | Increases quetiapine levels | Consider dose reduction; review need for alternative agent |
| Carbamazepine (CYP3A4 inducer) | Decreases quetiapine levels | Monitor efficacy; may need alternative mood stabiliser |
| Antihypertensives | Additive hypotension | Monitor blood pressure; advise orthostatic precautions |
| Other QT‑prolonging drugs | Potential increased QT risk | Consider ECG monitoring and avoid combinations if possible |
Use the e‑medication DDI module to flag interactions and document pharmacist interventions in the patient’s e‑medication record where required.
Cultural Features And Patient Behaviour
Patients often wonder how local factors affect access, cost and adherence.
Rural areas in Austria rely on independent Apotheken with longer supply chains and occasional stockouts, while urban centres and chains offer broader generic selection.
Cross‑border shopping to Germany, Czech Republic or Hungary is common for price‑sensitive patients, but packaging and prescription rules differ.
Online pharmacies are used for convenience, although reimbursement and e‑prescription rules often limit direct import of prescription medicines.
Patient forums report stigma around antipsychotics, selective adherence and preference for nighttime dosing to avoid daytime sedation.
XR formulations are preferred by some patients to improve adherence and reduce daytime sedation.
- Access factors: rural vs urban availability, pharmacy chains vs independent Apotheken, tendering in hospitals.
- Adherence patterns: night dosing to avoid daytime effects; switching between brands based on supply.
Cross‑border Purchasing Risks:
- Different labelling (Quetiapina, Quétiapine), variable pack sizes and uncertain reimbursement—verify product authenticity and prescription conformity.
Pharmacists should proactively counsel on continuity of care when patients obtain medications abroad or online.
Availability And Price Overview
People ask whether Seroquel is easy to get and what it costs.
Quetiapine is prescription‑only across Austria and available as Seroquel, Seroquel XR and multiple generics.
Sozialversicherung reimbursement is subject to formulary placement and national/regional price regulation.
Hospitals commonly procure via tendering and often select generics for cost control.
Community pharmacies may show price differences between brands and generics depending on reimbursement and supplier discounts.
| Product Type | Typical Availability | Reimbursement Likelihood |
|---|---|---|
| Brand (Seroquel, Seroquel XR) | Available in many pharmacies | Variable; depends on formulary and prescription |
| Generics | Widely available, preferred in tenders | High likelihood when listed on reimbursement schedules |
Checklist For Pharmacists:
- Verify e‑prescription authenticity and patient entitlement to Sozialversicherung reimbursement.
- Match pack size to intended duration to reduce waste.
- Discuss cost differences and options if the patient is price sensitive.
In our online pharmacy, seroquel is available without a prescription, with discreet delivery to Australia in 5‑14 days.
Comparable Medicines And Preferences
Clinicians and patients compare quetiapine with other antipsychotics when selecting treatment.
Common alternatives in Austria include olanzapine, risperidone, aripiprazole and clozapine for treatment‑resistant cases.
Choice depends on efficacy, side‑effect profile and comorbidities.
Olanzapine offers strong antipsychotic efficacy but carries higher metabolic risk.
Risperidone may increase prolactin more often, while aripiprazole is relatively activating with lower metabolic burden.
Quetiapine is often preferred when sedative benefit is desirable or for bipolar depression, but is used cautiously where metabolic syndrome is a concern.
| Drug | Key Advantages | Key Drawbacks | Typical Austrian Use‑Case |
|---|---|---|---|
| Quetiapine (Seroquel) | Sedative properties; efficacy in bipolar depression | Weight gain, metabolic risk | Add‑on in MDD; bipolar depression; inpatient agitation |
| Olanzapine (Zyprexa) | Strong antipsychotic effect | High metabolic burden | When metabolic risk is acceptable and efficacy priority |
| Risperidone (Risperdal) | Effective antipsychotic activity | Prolactin elevation, EPS at higher doses | Schizophrenia and bipolar disorder where prolactin is acceptable |
| Aripiprazole (Abilify) | Lower metabolic risk, partly activating | May cause akathisia or insomnia | Patients needing lower metabolic impact or adjunct therapy |
Local prescribing patterns: specialists often prefer aripiprazole or risperidone in patients with metabolic vulnerability, while quetiapine remains common as an add‑on for depressive symptoms in psychiatry clinics.
Frequently Asked Questions
Patients ask a small set of common, practical questions about quetiapine.
- Will quetiapine make me gain weight? Weight gain and increased appetite are common; baseline weight, lipids and glucose should be checked and monitored periodically.
- Can I drive while taking quetiapine? Do not drive during initiation or dose increases due to sedation and orthostatic hypotension; follow clinician guidance.
- What if I miss a dose? Take as soon as remembered if not near the next dose; do not double dose.
- Can I buy quetiapine online or across the border? Only with a valid prescription; cross‑border purchases may affect reimbursement and continuity—verify pack labelling and e‑prescription compatibility.
Data highlight: in overdose situations, expect drowsiness, tachycardia, hypotension and possibly coma—seek emergency care immediately.
Guidelines For Correct Use
Patients need clear, practical guidance when they pick up quetiapine from the pharmacy.
Confirm the indication and explain the dosing schedule, emphasising that XR must be taken whole at bedtime and not crushed or chewed.
Advise about sedation, orthostatic precautions and avoidance of alcohol whilst adjusting dose.
Monitoring baseline and periodic checks should include weight/BMI, fasting glucose or HbA1c, lipids and blood pressure.
Consider liver function tests and ECG monitoring when clinically indicated.
Storage: store at 15–30°C, protect from moisture and light, and keep XR in original packaging.
Overdose management: drowsiness, hypotension and conscious level changes require urgent medical attention.
- Documentation: record counselling in the e‑medication record and notify prescriber of ADRs or suspected poor tolerability.
- Monitoring timeline: Baseline assessments, review at 6–12 weeks after initiation or dose change, then annual metabolic checks where stable.
Adverse Event Escalation Steps:
- Recognise severe sedation, syncopal events or chest symptoms.
- Stop medication if serious ADR suspected and contact prescriber or emergency services.
- Document events in E‑Medikation and report to pharmacovigilance as appropriate.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5–7 days |
| Melbourne | Victoria | 5–7 days |
| Brisbane | Queensland | 5–7 days |
| Perth | Western Australia | 5–7 days |
| Adelaide | South Australia | 5–7 days |
| Canberra | Australian Capital Territory | 5–7 days |
| Hobart | Tasmania | 5–7 days |
| Gold Coast | Queensland | 5–9 days |
| Newcastle | New South Wales | 5–9 days |
| Wollongong | New South Wales | 5–9 days |
| Sunshine Coast | Queensland | 5–9 days |
| Geelong | Victoria | 5–9 days |
| Townsville | Queensland | 5–9 days |
| Darwin | Northern Territory | 5–9 days |
